Joung B, Lee JM, Lee KH, Kim TH, Choi EK, Lim WH, et al. Korean guideline of atrial fibrillation management. Korean Circ J. 2018;48(12):1033–80.
Lee H, Kim TH, Baek YS, Uhm JS, Pak HN, Lee MH, et al. The trends of atrial fibrillation-related hospital visit and cost, treatment pattern and mortality in Korea: 10-year nationwide sample cohort data. Korean Circ J. 2017;47(1):56–64.
Kim D, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Increasing trends in hospital care burden of atrial fibrillation in Korea, 2006 through 2015. Heart. 2018;104(24):2010–7.
Kim D, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. 10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population. Am Heart J. 2018;202:20–6.
Wortmann M. Dementia: a global health priority - highlights from an ADI and World Health Organization report. Alzheimers Res Ther. 2012;4(5):40.
Patterson C. International AsD. World Alzheimer report 2018: Alzheimer’s Disease International; 2018.
Bunch TJ, Weiss JP, Crandall BG, May HT, Bair TL, Osborn JS, et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Heart Rhythm. 2010;7(4):433–7.
Kim D, Yang PS, Yu HT, Kim TH, Jang E, Sung JH, et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. Eur Heart J. 2019;40(28):2313–23.
Singh-Manoux A, Fayosse A, Sabia S, Canonico M, Bobak M, Elbaz A, et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. Eur Heart J. 2017;38(34):2612–8.
Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial fibrillation and dementia in a population-based study. Rotterdam Study Stroke. 1997;28(2):316–21.
Dublin S, Anderson ML, Haneuse SJ, Heckbert SR, Crane PK, Breitner JC, et al. Atrial fibrillation and risk of dementia: a prospective cohort study. J Am Geriatr Soc. 2011;59(8):1369–75.
Marengoni A, Qiu C, Winblad B, Fratiglioni L. Atrial fibrillation, stroke and dementia in the very old: a population-based study. Neurobiol Aging. 2011;32(7):1336–7.
Rastas S, Verkkoniemi A, Polvikoski T, Juva K, Niinisto L, Mattila K, et al. Atrial fibrillation, stroke, and cognition: a longitudinal population-based study of people aged 85 and older. Stroke. 2007;38(5):1454–60.
Dagres N, Chao TF, Fenelon G, Aguinaga L, Benhayon D, Benjamin EJ, et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Europace. 2018;20(9):1399–421.
Gaita F, Corsinovi L, Anselmino M, Raimondo C, Pianelli M, Toso E, et al. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. J Am Coll Cardiol. 2013;62(21):1990–7.
de la Torre JC. Is Alzheimer’s disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3(3):184–90.
Han F, Ali Raie A, Shioda N, Qin ZH, Fukunaga K. Accumulation of beta-amyloid in the brain microvessels accompanies increased hyperphosphorylated tau proteins following microsphere embolism in aged rats. Neuroscience. 2008;153(2):414–27.
Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch Neurol. 2010;67(7):835–41.
Chopard R, Piazza G, Gale SA, Campia U, Albertsen IE, Kim J, et al. Dementia and atrial fibrillation: pathophysiological mechanisms and therapeutic implications. Am J Med. 2018;131(12):1408–17.
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215–22.
Friberg L, Rosenqvist M. Less dementia with oral anticoagulation in atrial fibrillation. Eur Heart J. 2018;39(6):453–60.
Friberg L, Andersson T, Rosenqvist M. Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation. Eur Heart J. 2019;40(28):2327–35.
Mongkhon P, Fanning L, Lau WCY, Tse G, Lau KK, Wei L, et al. Oral anticoagulant and reduced risk of dementia in patients with atrial fibrillation: A population-based cohort study. Heart Rhythm. 2020;17(5 Pt A):706–13.
Flaker GC, Pogue J, Yusuf S, Pfeffer MA, Goldhaber SZ, Granger CB, et al. Cognitive function and anticoagulation control in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3(3):277–83.
Jacobs V, Woller SC, Stevens S, May HT, Bair TL, Anderson JL, et al. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia. Heart Rhythm. 2014;11(12):2206–13.
Madhavan M, Hu TY, Gersh BJ, Roger VL, Killian J, Weston SA, et al. Efficacy of warfarin anticoagulation and incident dementia in a community-based cohort of atrial fibrillation. Mayo Clin Proc. 2018;93(2):145–54.
Lovelock CE, Cordonnier C, Naka H, Al-Shahi Salman R, Sudlow CL, Sorimachi T, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke. 2010;41(6):1222–8.
van Norden AG, van den Berg HA, de Laat KF, Gons RA, van Dijk EJ, de Leeuw FE. Frontal and temporal microbleeds are related to cognitive function: the Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Cohort (RUN DMC) Study. Stroke. 2011;42(12):3382–6.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.
Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke. 2015;46(9):2555–61.
Chen N, Lutsey PL, MacLehose RF, Claxton JS, Norby FL, Chamberlain AM, et al. Association of oral anticoagulant type with risk of dementia among patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7(21):e009561.
Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol. 2016;118(2):210–4.
Sogaard M, Skjoth F, Jensen M, Kjaeldgaard JN, Lip GYH, Larsen TB, et al. Nonvitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients and risk of dementia: a nationwide propensity-weighted cohort study. J Am Heart Assoc. 2019;8(11):e011358.
Zhang C, Gu ZC, Shen L, Pan MM, Yan YD, Pu J, et al. Non-vitamin K antagonist oral anticoagulants and cognitive impairment in atrial fibrillation: insights from the meta-analysis of over 90,000 patients of randomized controlled trials and real-world studies. Front Aging Neurosci. 2018;10:258.
Kim D, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS, et al. Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation. Europace. 2021;23(2):184–95.
Kim D, Yang PS, Jang E, Tae YuH, Kim TH, Uhm JS, et al. Blood pressure control and dementia risk in midlife patients with atrial fibrillation. Hypertension. 2020;75(5):1296–304.
Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic stroke. Stroke. 2012;43(1):265–70.
Nakamura T, Okishige K, Kanazawa T, Yamashita M, Kawaguchi N, Kato N, et al. Incidence of silent cerebral infarctions after catheter ablation of atrial fibrillation utilizing the second-generation cryoballoon. Europace. 2017;19(10):1681–8.
Deneke T, Jais P, Scaglione M, Schmitt R, Di Biase L, Christopoulos G, et al. Silent cerebral events/lesions related to atrial fibrillation ablation: a clinical review. J Cardiovasc Electrophysiol. 2015;26(4):455–63.
Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39(32):2942–55.
Jin MN, Kim TH, Kang KW, Yu HT, Uhm JS, Joung B, et al. Atrial fibrillation catheter ablation improves 1-year follow-up cognitive function, especially in patients with impaired cognitive function. Circ Arrhythm Electrophysiol. 2019;12(7):e007197.
Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. Eur Heart J. 2016;37(31):2478–87.
Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;18(10):1455–90.
Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: The CABANA randomized clinical trial. JAMA. 2019;321(13):1261–74.
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–27.
Bunch TJ, Crandall BG, Weiss JP, May HT, Bair TL, Osborn JS, et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(8):839–45.
Kim D, Yang PS, Sung JH, Jang E, Yu HT, Kim TH, et al. Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study. Eur Heart J. 2020;41(47):4483–93.
Camm AJ. Does ablation of atrial fibrillation reduce the likelihood of dementia? A step closer but not yet there. Eur Heart J. 2020;41(47):4494–6.